Your session is about to expire
← Back to Search
200 mg ecopipam HCL for Long QT Syndrome
Study Summary
This trial tested a drug to see how it affects the heart's electrical activity and its ability to pump blood.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Frequently Asked Questions
Is this research endeavor recruiting individuals older than 45 years of age?
"The criteria for participation in this medical trial includes being under 55 years and over 18."
Has the FDA sanctioned ecopipam HCL at a dosage of 200 mg?
"Due to the limited data on safety and efficacy, our team has assigned a score of 1 for 200 mg ecopipam HCL. This is in accordance with its Phase 1 classification."
Does this experiment have a current recruitment period for participants?
"Affirmative, the information hosted on clinicaltrials.gov elucidates that enrollment is open for this medical experiment which was initially published on March 15th 2023 and subsequently altered on April 21st 2023. The investigation seeks to recruit 32 individuals from a single location."
How many subjects are participating in the current clinical investigation?
"That is correct. Per the public record hosted on clinicaltrials.gov, this medical trial has been open since March 15th 2023 and it still recruiting patients today. Approximately 32 people are needed to be enrolled from a single research centre."
What prerequisites must be fulfilled in order to join this clinical trial?
"Prospective participants for this medical trial must have long qt syndrome, with an age range between 18 and 55. 32 individuals are currently being sought after to enroll in the study."
Share this study with friends
Copy Link
Messenger